CANNIM has today announced a world first as it releases its Jamaican grown medical cannabis for patients in the UK. This is the first legal shipment of medical cannabis to reach the UK from Jamaica and follows on from successful legal imports into Australia and Germany.
Released under the Lumir brand, Lumir WT2/JA is grown in the foothills of Jamaica’s famous Rio Minho River at Cannims’ GMP and GACP compliant farm, which has been operating since 2018. The warm and sunny climate combined with local expertise delivers a medical cannabis flower unlike any other in the world, which UK patients will now benefit from.
“Jamaica is world famous for growing cannabis,” Stuart Marsh, Chief Commercial Officer of Cannim said. “We established our farm in 2018 and not only is it able to export high quality medical cannabis around the world, but it also brings significant benefits to Jamaicans as well. Jamaica’s GDP per capita is just $5,730 (US), around one tenth of the UK, so we are bringing employment and security to our staff and their families. We have also established a supply of clean drinking water for the local town and given space for local farmers to use the land not under cultivation.”
Jamaican medical cannabis flower joins the Lumir oils that are currently available for prescription to patients – THC25, 12.5:12.5, 25:25 and a broad spectrum CBD100. Named after Professor Hanus Lumir, the scientist who discovered Anandamide, the Lumir range is a testimony to his pioneering science and ongoing drive to break down barriers to accessing this medicine.
Tim Henley, UK Commercial Manager for Cannim said: “The Lumir range of medical cannabis is dedicated to meeting the needs of patients, bringing them a range of solutions to their conditions on a consistent basis, as well as working to make access simpler for all through education and support.”
While Lumir medical cannabis oils are already widely prescribed in the market by specialists in the UK, Dispensary Green is the first to see prescriptions for the Lumir WT2/JA and have the stock for their respective patients.
Chris Ashton, Chief Commercial Officer of Lyphe group who run TMCC said “We are excited to be the first group to be able to bring iconic Jamaican cannabis to patients in the UK through our partnership with Cannim and we look forward to expanding the offering to our patients in the near future.”